Pulmonary Medicine / 2018 / Article / Tab 1

Research Article

Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension

Table 1

Descriptive statistics of patients enrolled in the study.

Variable Patients who tolerated PAHST Patients who did not tolerate PAHST
Number of patientsMeanSENumber of patientsMeanSE

Age2064.62.93667.44.61
CCI203.800.3664.00.37
PAPm2051.32.71648.83.45
PAWP2023.60.84627.02.80
TPG2027.72.53621.82.27
PVR196.50.7867.142.47
DPG208.31.6564.22.06
CO194.460.2163.680.25
Vascular compromise1971.21.20671.42.47

WHO-baseline202.700.2163.000.37
WHO-3 months182.330.23
WHO-6 months182.220.21
WHO-9 months162.060.21
6-MWD-baseline23276.038.506268.050.52
6-MWD-3 months17360.529.01
6-MWD-6 months17343.922.99
6-MWD-9 months15364.634.85
6-MWD (% pre)-baseline2356.46.83658.38.99
6-MWD (% pre)-3 months1772.63.82
6-MWD (% pre)-6 months1772.83.58
6-MWD (% pre)-9 months1574.14.26
Survival (in days)201350.8173.44

PAHST = Pulmonary Arterial Hypertension Specific Therapy, CCI = Charlson Comorbidities Index, PAPm = Mean Pulmonary Artery Pressure (mmHg), PAWP = Pulmonary Arterial Wedge Pressure (mmHg), CO = Cardiac Output (L/min), TPG = Transpulmonary Gradient (mmHg), DPG = Diastolic Pressure Gradient (mmHg), PVR = Pulmonary Venous Resistance (WU), WHO = World Health Organization functional class, 6-MWD = 6-minute walk distance (meters), and SE = standard error.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.